Abstract:Alzheimer's disease is a neurodegenerative disorder characterized by cognitive dysfunction and behavioral abnormalities. Neuroinflammatory plaques formed through the extracellular deposition of amyloid-β proteins, as well as neurofibrillary tangles formed by the intracellular deposition of hyperphosphorylated tau proteins, comprise two typical pathological features of Alzheimer's disease. Besides symptomatic treatment, there are no effective therapies for delaying Alzheimer's disease progression. MicroRNAs (miR) are small, non-coding RNAs that negatively regulate gene expression at the transcriptional and translational levels and play important roles in multiple physiological and pathological processes. Indeed, miR-146a, a NF-κB-regulated gene, has been extensively implicated in the development of Alzheimer's disease through several pathways. Research has demonstrated substantial dysregulation of miR-146a both during the initial phases and throughout the progression of this disorder. MiR-146a is believed to reduce amyloid-β deposition and tau protein hyperphosphorylation through the TLR/IRAK1/TRAF6 pathway; however, there is also evidence supporting that it can promote these processes through many other pathways, thus exacerbating the pathological manifestations of Alzheimer's disease. It has been widely reported that miR-146a mediates synaptic dysfunction, mitochondrial dysfunction, and neuronal death by targeting mRNAs encoding synaptic-related proteins, mitochondrial-related proteins, and membrane proteins, as well as other mRNAs. Regarding the impact on glial cells, miR-146a also exhibits differential effects. On one hand, it causes widespread and sustained inflammation through certain pathways, while on the other hand, it can reverse the polarization of astrocytes and microglia, alleviate neuroinflammation, and promote oligodendrocyte progenitor cell differentiation, thus maintaining the normal function of the myelin sheath and exerting a protective effect on neurons. In this review, we provide a comprehensive analysis of the involvement of miR-146a in the pathogenesis of Alzheimer's disease. We aim to elucidate the relationship between miR-146a and the key pathological manifestations of Alzheimer's disease, such as amyloid-β deposition, tau protein hyperphosphorylation, neuronal death, mitochondrial dysfunction, synaptic dysfunction, and glial cell dysfunction, as well as summarize recent relevant studies that have highlighted the potential of miR-146a as a clinical diagnostic marker and therapeutic target for Alzheimer's disease.

Progress of research on microRNA and Alzheimer's disease]

Down‐regulated Expression of Microrna‐338‐5p Contributes to Neuropathology in Alzheimer's Disease

Research Progress of Micro Ribonucleic Acid in Cerebral Ischemia

Functions of MicroRNA in Nervous System Regulation

MicroRNA-139 Modulates Alzheimer's-associated Pathogenesis in SAMP8 Mice by Targeting Cannabinoid Receptor Type 2.

MicroRNAs: pioneering regulators in Alzheimer's disease pathogenesis, diagnosis, and therapy

Genome-wide Analysis of Mirna Signature in the APPswe/PS1ΔE9 Mouse Model of Alzheimer's Disease.

Research Progress of microRNA-761

MicroRNAs in Alzheimer’s Disease: Diagnostic Markers or Therapeutic Agents?

Potential Implications of miRNAs in the Pathogenesis, Diagnosis, and Therapeutics of Alzheimer’s Disease

Development of Microrna-Based Therapeutics for Central Nervous System Diseases.

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

The complex effects of miR-146a in the pathogenesis of Alzheimer's disease

MicroRNA Alteration, Application as Biomarkers, and Therapeutic Approaches in Neurodegenerative Diseases

MicroRNAs as Potential Orchestrators of Alzheimer's Disease-Related Pathologies: Insights on Current Status and Future Possibilities

Insights into the Role of microRNAs as Clinical Tools for Diagnosis, Prognosis, and as Therapeutic Targets in Alzheimer's Disease

Alzheimer’s Disease and microRNA-132: A Widespread Pathological Factor and Potential Therapeutic Target

Identification of microRNA-mRNA Regulatory Networks with Therapeutic Values in Alzheimer's Disease by Bioinformatics Analysis

P-Glycoprotein Expression, Tumor Weight, Age, and Relapse in Patients with Stage I and II Favorable-Histology Wilms’ Tumor

Mir-34A, a Microrna Up-Regulated in a Double Transgenic Mouse Model of Alzheimer's Disease, Inhibits Bcl2 Translation

A critical evaluation of neuroprotective and neurodegenerative MicroRNAs in Alzheimer's disease